Bioaffinity Technologies, Inc. (BIAF) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bioaffinity Technologies, Inc. on August 14, 2023. The filing serves to disseminate a press release containing financial information for the quarter ended June 30, 2023. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols BIAF (Common Stock) and BIAFW (Warrants).
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly references a press release (Exhibit 99.1) as the source for these figures but does not embed the data within the 8-K text itself.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to prior periods. It only confirms the issuance of a press release regarding the quarter ended June 30, 2023.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2023) for actual financial figures for the quarter ended June 30, 2023.
- Verify the company's status as an emerging growth company (indicated as yes in the filing).
- Confirm the trading status of Common Stock (BIAF) and Warrants (BIAFW) on Nasdaq.
- Note that the financial data in this 8-K is not incorporated by reference into future filings.